Atrion (NASDAQ:ATRI) Rating Lowered to Sell at StockNews.com

StockNews.com lowered shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

Atrion Stock Up 0.8 %

NASDAQ ATRI opened at $426.88 on Wednesday. Atrion has a 52 week low of $274.98 and a 52 week high of $615.30. The firm has a market capitalization of $751.31 million, a P/E ratio of 38.70 and a beta of 0.60. The company has a 50-day moving average price of $408.82 and a 200-day moving average price of $364.93.

Atrion (NASDAQ:ATRI) last released its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The firm had revenue of $43.58 million during the quarter.

Atrion Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were given a dividend of $2.20 per share. This represents a $8.80 annualized dividend and a dividend yield of 2.06%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion’s payout ratio is currently 79.78%.

Institutional Investors Weigh In On Atrion

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Exchange Traded Concepts LLC purchased a new stake in Atrion in the 3rd quarter worth approximately $333,000. Bank of New York Mellon Corp increased its holdings in Atrion by 2.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock worth $4,134,000 after acquiring an additional 194 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Atrion by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock worth $4,291,000 after acquiring an additional 243 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Atrion in the 3rd quarter worth approximately $208,000. Finally, SG Americas Securities LLC purchased a new stake in Atrion in the 4th quarter worth approximately $108,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.